Skip to main content

Advertisement

Table 2 Baseline patient characteristics

From: A phase II study of dacetuzumab (SGN-40) in patients with relapsed diffuse large B-cell lymphoma (DLBCL) and correlative analyses of patient-specific factors

Characteristic Median [range] or No. (%)
Age, years 72 [17–85]
Male gender 28 (61)
ECOG status  
  0 16 (35)
  1 23 (50)
  2 6 (13)
  Unknown 1 (2)
Time since diagnosis, years 2.9 [0–21]
Number of prior systemic therapies 3 [19]
Prior ASCT 16 (35)
Diagnosis after confirmatory review  
  DLBCL 40 (87)
  Follicular NHL (grade 2) 3 (7)
  Marginal zone 2 (4)
  Diffuse large cell NHL, lineage undetermined 1 (2)
DLBCL subtype  
  GCB 14 (30)
  Non-GCB 14 (30)
  Missing 18 (39)
CD40 staining intensity  
  0 1 (2)
  1+ 2 (4)
  2+ 13 (28)
  3+ 25 (54)
  Not available 5 (11)
  1. ECOG, Eastern Cooperative Oncology Group; ASCT, autologous stem cell transplantation; DLBCL, diffuse large B-cell lymphoma; GCB, germinal center B-cell; NHL, non-Hodgkin lymphoma.